Short interest in TransCode Therapeutics Inc (NASDAQ:RNAZ) increased during the last reporting period, rising from 339.77K to 2.55M. This put -% of the company's publicly available shares short.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price ...

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of ...